Oseltamivir: Difference between revisions
| [unchecked revision] | [unchecked revision] |
MDElliottMD (talk | contribs) parser-claude batch MedTemplate pre-fill, Top 300 #250 |
MDElliottMD (talk | contribs) home-claude category backfill (parser-claude gap closure) |
||
| Line 21: | Line 21: | ||
== References == | == References == | ||
<references /> | <references /> | ||
[[Category:Antivirals]] | |||
[[Category:Neuraminidase inhibitors]] | |||
[[Category:Anti-influenza agents]] | |||
Latest revision as of 10:43, 23 May 2026
Oseltamivir
Tamiflu
Experience
No personal reports yet
No clinical reports yet
Log in to add your own experience.
Problems
No problems yet. Be the first to suggest one.
+ Add a problemTitration strategies
No titration strategies yet. Be the first to suggest one.
Effects
No effects listed yet. Be the first to suggest one.
Relevant anecdote
No anecdotes yet. Share a relevant one.
Relevant Literature
No literature entries yet.
Log in to submit relevant literature.
Summary
Common uses
Influenza A and B treatment (within 48 hours of symptom onset)0, Post-exposure influenza prophylaxis0, Outbreak control in long-term care facilities0
Pharmacy
Starting dose
Treatment: 75 mg PO BID × 5 days (adult); pediatric weight-based; prophylaxis: 75 mg PO once daily × 7-10 days
Preparations
30, 45, 75 mg capsules; 6 mg/mL oral suspension
US FDA Max
150 mg/d (treatment)
Pharmacology
Routes
Oral
Onset
Symptom shortening detectable within 24-48 hours of starting (small absolute benefit; ~1 day reduction in symptom duration)
Duration
12 hours
Half-life
~6-10 hours (oseltamivir carboxylate, the active metabolite)[1]
Bioavailability
~75% (oral, as the active carboxylate after hepatic esterase activation)[1]
Pregnancy
Generally used when influenza treatment is indicated; pregnancy is a recognized risk factor for severe influenza.[citation needed]
Legal status
Rx-only in US
Purported mechanism
Oseltamivir is an ester prodrug activated by hepatic carboxylesterase to oseltamivir carboxylate, a competitive inhibitor of influenza A and B neuraminidase; blocking neuraminidase prevents sialic acid cleavage from host glycoproteins, trapping newly assembled virions on the cell surface and limiting spread to neighboring cells.0 Modest clinical benefit (~1 day faster symptom resolution in healthy adults treated within 48 hours); larger absolute benefit in hospitalized, high-risk, and severely ill patients. Neuropsychiatric events (delirium, abnormal behavior, especially in children) are FDA-labeled adverse effects of uncertain causal contribution[1].
References
- ↑ 1.0 1.1 1.2 FDA Prescribing Information, Tamiflu (oseltamivir phosphate), Genentech, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021087s066lbl.pdf